

Joint Working Executive Summary -

Celgene Website declaration

All joint working agreements must be certified in accordance with Clause 14.1

JW Partner(s)	<p>NHS Greater Glasgow &amp; Clyde</p> <p>Novartis Pharmaceuticals UK Limited</p> <p>Celgene Limited</p>
Project period	Project ran from January 2015 to July 2019
Project Name	<b>NHS Greater Glasgow &amp; Clyde Molecular Diagnostic Pathway Development</b>
<p>Joint working project summary: (sufficient to give a reader a clear understanding of the work to be undertaken)</p>	<p>This Joint Working Project aimed to introduce new molecular techniques into routine clinical practice. The project objectives included:</p> <ol style="list-style-type: none"> <li>1. Identifying companion or stand-alone diagnostics for introduction in patient pathways across Scotland and to inform on the current Scottish process to approve the mentioned companion or stand-alone diagnostics for the relevant medicines carried out by the Molecular Pathology Evaluation Panel (“MPEP”)/ Molecular Pathology Consortium (“MPC”) (The “Scottish Process”)</li> <li>2. Developing pathways across Scotland incorporating relevant companion or stand-alone diagnostics and appropriate sequential testing strategies including Next Generation Sequencing (“NGS”) and other novel technologies to routine practice</li> <li>3. Development and evaluation of bioinformatics pipelines for somatic cancer in collaboration with University of Glasgow colleagues</li> <li>4. Develop a protocol to evaluate genomic signatures in response to chemotherapy</li> <li>5. Provide a finalized protocol for genetic testing to support clinical trials</li> <li>6. Capture and utilize the project service data to demonstrate that the service is financially sustainable for NSD</li> <li>7. Attend a Scotland wide educational meeting where the NHS, academia and industry are represented to promote the benefits of Joint Working Project between industry and the NHS in Scotland</li> </ol>
Expected patient outcomes for this project	Improving patient outcomes by incorporating a prognostic and diagnostic tool in the relevant patient pathways across Scotland. Early identification of companion diagnostics to inform feasibility for SMC approval. Streamline and consolidate testing strategies for more effective patient management.

Start Date & Duration	January 2015 Project end date: July 2019
--------------------------	---